Free Trial

Apollomics (APLM) News Today

Apollomics logo
$31.98 +12.48 (+64.00%)
Closing price 10/16/2025 04:00 PM Eastern
Extended Trading
$31.02 -0.97 (-3.02%)
As of 10/16/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Why Is Apollomics Up Today?

Apollomics Inc. (NASDAQ: APLM) is trading higher today on heavy volume after a string of company and market events that increased investor attention. Key drivers: Nasdaq confirmed Apollomics is in compliance with continued listing requirements (removing delisting risk), the stock experienced multiple LULD trading pauses amid high intraday activity, and short interest jumped sharply in September.

  • Positive Sentiment: Nasdaq confirmed Apollomics is compliant with continued listing requirements, cancelling a planned appeal hearing and ensuring the company's securities remain listed — a clear de‑risking event that can restore investor confidence and remove delisting overhang. Apollomics Announces Continued Listing on The Nasdaq Stock Market
  • Neutral Sentiment: Multiple Limit Up/Limit Down (LULD) trading pauses were triggered across Oct. 15–16, indicating elevated intraday volatility and unusually high order flow — this explains intermittent halts and the large jump in traded volume but is not a directional fundamental signal on its own.
  • Negative Sentiment: Short interest surged to ~75,500 shares as of Sept. 30 (about 14.0% of float), a reported ~2,696% increase from mid‑September; while the short‑interest ratio is modest (~1.5 days), the large percentage of shares sold short signals substantial bearish bets or hedging activity and adds downside pressure and volatility risk going forward.

Investor takeaway: the Nasdaq compliance news is the primary positive catalyst supporting the rally and reduced delisting risk, LULD pauses reflect heavy speculative trading, and the spike in short interest raises the potential for continued volatility (and short‑squeeze dynamics). Monitor clinical updates for vebreltinib (APL‑101) and any further regulatory or volume developments for near‑term moves.

Posted 7h agoAI Generated. May Contain Errors.

APLM Latest News

nasdaq resumes trading in Apollomics
Apollomics, Inc. Company Operational Continuity Update
Nasdaq halts Apollomics
Biotech fails trials for its leukemia drug
Apollomics Inc trading halted, volatility trading pause
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
Apollomics announces approval, date for 1-for-100 reverse share split
Apollomics GAAP EPS of -$2.32
Get Apollomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

APLM Media Mentions By Week

APLM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

APLM
News Sentiment

0.24

0.68

Average
Medical
News Sentiment

APLM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

APLM Articles
This Week

25

1

APLM Articles
Average Week

Get the Latest News and Ratings for APLM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Apollomics and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NASDAQ:APLM) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners